ReviewFuture oncology (London, England)2026

Evaluating datopotamab deruxtecan (Dato-DXd) as a novel treatment option for EGFR-mutated non-small cell lung cancer.

Olga Tsvetkova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.